Cargando…
P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS
Autores principales: | Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Jacobsen, E. D., Gritti, G., Pinter-Brown, L., Isutzu, K., Cohan, D., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., Horwitz, S. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430404/ http://dx.doi.org/10.1097/01.HS9.0000847552.42271.7c |
Ejemplares similares
-
P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY
por: Mehta-Shah, Neha, et al.
Publicado: (2023) -
P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)
por: Vorobyev, V., et al.
Publicado: (2022) -
Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study
por: Flinn, Ian W., et al.
Publicado: (2018) -
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
por: Davids, Matthew S., et al.
Publicado: (2020) -
Riccardo primo
por: Handel, George Frideric, 1685-1759
Publicado: (1996)